Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Micallef, Ivana N.; Maurer, Mathew S.; Wiseman, Gregory A.; Nikcevich, Daniel A.; Kurtin, Paul J.; Cannon, Michael W.; Pérez, Domingo G.; Soori, Gamini S.; Link, Brian K.; Habermann, Thomas M.; Witzig, Thomas E.

doi:10.1182/blood-2011-02-336990

Cited by 135 publications

(92 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have shown that a negative early PET is highly predictive of a negative end-of-treatment PET [5][6][7]39 ; however, some investigators [40][41][42] have reported recently that midtreatment PET failed to predict different outcomes in aggressive NHL patients. These discordant findings in the setting of aggressive NHL are outlined in Table 2.…”

Section: Discussionmentioning

confidence: 99%

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

Herein, we report on direct preparation of macroporous polyimide (PI) films with pores distributing on one side, the method of which relies on sedimentation of ceramic spheres in polyamic acid (PAA) solutions in a gravitational field and imidization of PAA/ceramic spheres mixtures to obtain PI/ceramic spheres hybrid films followed by curing in dilute hydrofluoric (HF) acid. In this strategy, the curing of the hybrid films in HF acid leads to the formation of pores. The introduction of pores makes the room‐temperature dielectric constants of the macroporous films lower than that of pure PI film. Moreover, the macroporous PI films have improved Young's moduli and higher thermal stability in nitrogen atmosphere. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 104: 261–266, 2007

show abstract

Section: Discussionmentioning

confidence: 99%

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…21,32 Secondly, some recent studies have shown end-of-treatment PET to carry the highest PPV compared to iPET. 16,41,42 Consequently, early biopsy of FDG-avid sites has been recommended, since, in one large prospective study, iPET-positive patients who were biopsy-negative displayed outcomes equivalent to those for iPET-negative patients, with the caveat that both patient groups were switched to R-ICE treatment intensification. 43 As in the vast majority of studies, however, we did not assess biopsies taken from iPETpositive residual masses.…”

Section: Discussionmentioning

confidence: 99%

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

et al. 2016

View full text Add to dashboard Cite

I n the treatment of diffuse large B-cell lymphoma, a persistently positive [ 18 F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%. Patients received 4 cycles of R-CHOP-14, followed by a centrally-reviewed PET performed at day 17-20 of cycle 4 and assessed according to International Harmonisation Project criteria. Median age of the 151 evaluable patients was 57 years, with 79% stages 3-4, 54% bulk, and 54% International Prognostic Index 3-5. Among the 143 patients undergoing interim PET, 101 (71%) were PET-negative (96 of whom completed R-CHOP), 42 (29%) were PETpositive (32 of whom completed R-ICE and 90Y-ibritumomab tiuxetan-BEAM). At a median follow up of 35 months, the 2-year progressionfree survival for PET-positive patients was 67%, a rate similar to that for

show abstract

“…49,50 Subsequent prospective studies have not found such a dramatic difference, and some patients with a positive interim PET result may still have a favorable outcome. 51 One approach under investigation for patients with negative early interim PET findings, particularly those with Hodgkin lymphoma, is to employ chemotherapy-reduction strategies. In advancedstage disease, in which higher doses of chemotherapy are indicated, omitting chemotherapy cycles or changing to less intensive chemotherapy could potentially spare treatment-related toxicity with the goal of maintaining efficacy.…”

Section: Interim Scans (To Direct Treatment)mentioning

confidence: 99%

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Ansell

Armitage

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma. I n most patients with lymphoma, positron emission tomographic (PET) scans show abnormalities at diagnosis. Normal findings on the scan after therapy is highly predictive of a good prognosis, particularly in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma. However, the optimal application of PET scans to the management of all patients with lymphoma remains problematic. The major controversies include the optimal timing of PET scans (for staging, during therapy, after completion of therapy, surveillance in remission), standardization of PET scan interpretation (visual interpretation compared with standard uptake value [SUV] calculation), what constitutes a positive PET scan result, and whether PET scans should be used to direct management (eg, does changing therapy in patients with positive findings on PET change outcome, should biopsies of sites with positive PET results be done routinely before a management change). Although a large body of literature addressing these topics exists, the studies are often difficult to compare, making definitive conclusions on all these issues difficult. The previously published studies often used different designs and variable reporting, making interpretation and comparison of the results difficult. In the early studies particularly, heterogeneous populations with different stages of disease and different histologic subtypes were included, making the clinical applicability of the studies' results difficult. More recent studies focusing on efforts to standardize the conduct and interpretation of PET scans and on riskadapted therapies based on interim PET scan results will, it is hoped, improve the management and outcome of patients with lymphoma. A literature search of PubMed from 1999 to 2011 was performed using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. We highlight the current standard use ...

show abstract

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Cited by 135 publications

References 38 publications

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Contact Info

Product

Resources

About

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Cited by 135 publications

References 38 publications

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Contact Info

Product

Resources

About

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma